{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:51:46Z","timestamp":1777949506961,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13135-7","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T02:38:02Z","timestamp":1774406282000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of bedaquiline, pretomanid, linezolid and moxifloxacin in drug-resistant tuberculosis patients in selected public hospitals in Ethiopia: a multicenter retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Bisrat","family":"Solomon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdurehman","family":"Seid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tigle","family":"Nadew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abel","family":"Werku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tigist","family":"Mesfin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Altaye","family":"Nigussie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etalemahu","family":"Sebro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robel","family":"Gemechu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eyerusalem","family":"Mekonnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bontu","family":"Abate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Eshetu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Workye","family":"Tigabie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melaku","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haimanot Tadesse","family":"Mulu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"13135_CR1","unstructured":"Global tuberculosis report 2025. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0.I G O."},{"key":"13135_CR2","unstructured":"World Health Organization. Tuberculosis: Multidrug-resistant Tuberculosis (MDR-TB) [Internet]. World Health Organization. 2024. Available from: https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/tuberculosis-multidrug-resistant-tuberculosis-(mdr-tb)."},{"key":"13135_CR3","unstructured":"Tuberculosis in the WHO African Region. 2023 progress update. Brazzaville: WHO African Region, 2023. Licence: CC BY-NC-SA 3.0 IGO. <African Region_2023 report.pdf>"},{"issue":"2","key":"13135_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4046\/trd.2022.0148","volume":"86","author":"MF Sazali","year":"2023","unstructured":"Sazali MF, Rahim S, Mohammad AH, Kadir F, Payus AO, Avoi R, et al. Improving Tuberculosis Medication Adherence: The Potential of Integrating Digital Technology and Health Belief Model. Tuberc Respir Dis (Seoul). 2023;86(2):82\u201393.","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"13135_CR5","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.2147\/PPA.S370520","volume":"16","author":"Z Grigoryan","year":"2022","unstructured":"Grigoryan Z, McPherson R, Harutyunyan T, Truzyan N, Sahakyan S. Factors Influencing Treatment Adherence Among Drug-Sensitive Tuberculosis (DS-TB) Patients in Armenia: A Qualitative Study. Patient Prefer Adherence. 2022;16:2399\u2013408.","journal-title":"Patient Prefer Adherence"},{"key":"13135_CR6","unstructured":"abay12w. National Training Manual_PMDT 2023 [Internet]. Scribd. 2023 [cited 2026 Feb 14]. Available from: https:\/\/www.scribd.com\/document\/833343575\/National-Training-Manual-PMDT-2023."},{"issue":"10","key":"13135_CR7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020;382(10):893\u2013902.","journal-title":"N Engl J Med"},{"issue":"2","key":"13135_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","volume":"12","author":"BT Nyang\u2019wa","year":"2024","unstructured":"Nyang\u2019wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respir Med. 2024;12(2):117\u201328.","journal-title":"Lancet Respir Med"},{"key":"13135_CR9","unstructured":"WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Geneva WHO Licence CC BY NC SA 3.0 IGO; 2022 2022."},{"key":"13135_CR10","unstructured":"https:\/\/traceth.net\/ethiopia-launches-programmatic-introduction-of-the-6-month-bpalm-bpal-regimen-for-rr-dr-tb [Internet]. https:\/\/traceth.net. 2023 [cited 2025 Oct 18]. Available from: treatment\/#:~:text=Ethiopia%20has%20officially%20launched%20the%20programmatic%20rollout%20of,regimen%20for%20the%20treatment%20of%20rifampicin-resistant%2Fmulti-drug%20resistant%20tuberculosis. Accessed 18 October 2025. Available from: https:\/\/traceth.net."},{"issue":"1","key":"13135_CR11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s12890-024-03350-w","volume":"24","author":"AH Kebede","year":"2024","unstructured":"Kebede AH, Mamo H. Multidrug-resistant tuberculosis treatment outcomes and associated factors at Yirgalem General Hospital, Sidama Region, South Ethiopia: a retrospective cohort study. BMC Pulm Med. 2024;24(1):527.","journal-title":"BMC Pulm Med"},{"key":"13135_CR12","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2147\/TCRM.S423163","volume":"19","author":"DL Achalu","year":"2023","unstructured":"Achalu DL, Mohammed FG, Teferi M. Magnitude and Impacts of Adverse Events of Injectable Containing Shorter Regimen in Programmatic Management of Multi-Drug Resistant Tuberculosis in Ethiopia: A Retrospective Cohort Study. Ther Clin Risk Manag. 2023;19:889\u2013901.","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"13135_CR13","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1186\/s12879-024-10205-6","volume":"24","author":"Z Bonsa","year":"2024","unstructured":"Bonsa Z, Tadesse M, Bekele E, Abeba G, Solomon E, Husen M, et al. Treatment outcomes and associated factors among patients with multidrug-resistant tuberculosis in Southwestern Oromia, Ethiopia: ten-year retrospective analysis. BMC Infect Dis. 2024;24(1):1305.","journal-title":"BMC Infect Dis"},{"issue":"null","key":"13135_CR14","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.2147\/IDR.S365394","volume":"15","author":"T Belachew","year":"2022","unstructured":"Belachew T, Yaheya S, Tilahun N, Gebrie E, Seid R, Nega T, et al. Multidrug-Resistant Tuberculosis Treatment Outcome and Associated Factors at the University of Gondar Comprehensive Specialized Hospital: A Ten-Year Retrospective Study. Infect Drug Resist. 2022;15(null):2891.","journal-title":"Infect Drug Resist"},{"issue":"2","key":"13135_CR15","doi-asserted-by":"publisher","first-page":"e0262318","DOI":"10.1371\/journal.pone.0262318","volume":"17","author":"MK Wakjira","year":"2022","unstructured":"Wakjira MK, Sandy PT, Mavhandu-Mudzusi AH. Treatment outcomes of patients with MDR-TB and its determinants at referral hospitals in Ethiopia. PLoS ONE. 2022;17(2):e0262318.","journal-title":"PLoS ONE"},{"key":"13135_CR16","doi-asserted-by":"crossref","unstructured":"Solomon B, Woldeamanuel Y, Ajeme T, Senkoro M, Manyazewal T. Adverse drug reactions and contributing factors in patients with drug-resistant tuberculosis: a 7-year retrospective cohort study in Addis Ababa, Ethiopia. J Clin Tuberc Other Mycobact Dis. 2025;39.","DOI":"10.1016\/j.jctube.2025.100515"},{"key":"13135_CR17","unstructured":"World Bank Open Data [Internet]. World Bank Open Data. 2026 [cited 2026 Feb 14]. Available from: https:\/\/data.worldbank.org\/indicator\/SP.POP.TOTL?locations=et-ET."},{"issue":"2","key":"13135_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.5588\/pha.20.0065","volume":"11","author":"E Tesema","year":"2021","unstructured":"Tesema E, Wares F, Bedru A, Negeri C, Molla Y, Gemechu D, et al. Experiences of introducing new drugs for drug-resistant TB at the ALERT Hospital, Addis Ababa, Ethiopia, 2017\u20132019. Public Health Action. 2021;11(2):50\u20132.","journal-title":"Public Health Action"},{"issue":"1","key":"13135_CR19","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1186\/s12879-025-11191-z","volume":"25","author":"M Hatiya","year":"2025","unstructured":"Hatiya M, Merid Y, Mola A, Belayneh F, Ali MM. Prevalence of drug-resistant Mycobacterium tuberculosis and its associated factors among tuberculosis patients attending Dilla university referral hospital, Ethiopia. BMC Infect Dis. 2025;25(1):797.","journal-title":"BMC Infect Dis"},{"key":"13135_CR20","doi-asserted-by":"publisher","first-page":"5266347","DOI":"10.1155\/2022\/5266347","volume":"2022","author":"T Kebede","year":"2022","unstructured":"Kebede T, Molla Sisay M. Attitudes of Healthcare Workers about Prevention and Control of Nosocomial Multidrug-Resistant Tuberculosis Infection in Two Top-Ranked Tuberculosis Specialized Public Hospitals of Ethiopia. Can J Infect Dis Med Microbiol. 2022;2022:5266347.","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"13135_CR21","first-page":"1","volume":"WHO\/HTM\/TB\/2015","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. Active tuberculosis drug-safety monitoring and management (aDSM) Framework for Implementation. World Health Organ Doc. 2015;WHO\/HTM\/TB\/201528:1\u201320. 2015.","journal-title":"World Health Organ Doc"},{"key":"13135_CR22","unstructured":"World Health Organization. Definitions and reporting framework for tuberculosis: 2013 revision (updated December 2014 and January 2020). Geneva: World Health Organization; 2020."},{"key":"13135_CR23","doi-asserted-by":"crossref","unstructured":"Linh NN, Viney K, Gegia M, Falzon D, Glaziou P, Floyd K, et al. World Health Organization treatment outcome definitions for tuberculosis: 2021 update. Eur Respir J. 2021;58(2).","DOI":"10.1183\/13993003.00804-2021"},{"key":"13135_CR24","unstructured":"10. Outcome definitions| TB Knowledge Sharing."},{"issue":"1","key":"13135_CR25","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s12879-019-3919-1","volume":"19","author":"MW Merid","year":"2019","unstructured":"Merid MW, Gezie LD, Kassa GM, Muluneh AG, Akalu TY, Yenit MK. Incidence and predictors of major adverse drug events among drug-resistant tuberculosis patients on second-line anti-tuberculosis treatment in Amhara regional state public hospitals; Ethiopia: a retrospective cohort study. BMC Infect Dis. 2019;19(1):286.","journal-title":"BMC Infect Dis"},{"key":"13135_CR26","unstructured":"Guidelines for Clinical and Programmatic Management of TB, TB\/HIV, DR-TB and Leprosy in Ethiopia. 7th ed. 2021. Ethiopia 2021."},{"key":"13135_CR27","unstructured":"Guideline on haemoglobin cutoffs to define anaemia in individuals and populations. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"13135_CR28","doi-asserted-by":"publisher","first-page":"883483","DOI":"10.3389\/fphar.2022.883483","volume":"13","author":"A Massud","year":"2022","unstructured":"Massud A, Syed Sulaiman SA, Ahmad N, Shafqat M, Chiau Ming L, Khan AH. Frequency and Management of Adverse Drug Reactions Among Drug-Resistant Tuberculosis Patients: Analysis From a Prospective Study. Front Pharmacol. 2022;13:883483.","journal-title":"Front Pharmacol"},{"key":"13135_CR29","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.2147\/IDR.S365394","volume":"15","author":"T Belachew","year":"2022","unstructured":"Belachew T, Yaheya S, Tilahun N, Gebrie E, Seid R, Nega T, et al. Multidrug-Resistant Tuberculosis Treatment Outcome and Associated Factors at the University of Gondar Comprehensive Specialized Hospital: A Ten-Year Retrospective Study. Infect Drug Resist. 2022;15:2891\u20139.","journal-title":"Infect Drug Resist"},{"key":"13135_CR30","unstructured":"6. Treatment of drug-resistant TB using longer regimens | TB Knowledge Sharing [Internet]. Who.int. 2018. Available from: https:\/\/tbksp.who.int\/en\/node\/3037."},{"key":"13135_CR31","doi-asserted-by":"publisher","unstructured":"The effectiveness and safety of bedaquiline, pretomanid and linezolid-based regimens for rifampicin-resistant tuberculosis in non-trial settings: a prospective cohort study in Belarus and Uzbekistan. Clin Infect Dis. 2025. https:\/\/doi.org\/10.1093\/cid\/ciaf035.","DOI":"10.1093\/cid\/ciaf035"},{"issue":"11","key":"13135_CR32","doi-asserted-by":"publisher","first-page":"e0310773","DOI":"10.1371\/journal.pone.0310773","volume":"19","author":"DF Wares","year":"2024","unstructured":"Wares DF, Mbenga M, Mirtskhulava V, Quelapio M, Slyzkyi A, Koppelaar I, et al. Introducing BPaL: Experiences from countries supported under the LIFT-TB project. PLoS ONE. 2024;19(11):e0310773.","journal-title":"PLoS ONE"},{"issue":"9","key":"13135_CR33","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","volume":"387","author":"F Conradie","year":"2022","unstructured":"Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med. 2022;387(9):810\u201323.","journal-title":"N Engl J Med"},{"key":"13135_CR34","doi-asserted-by":"crossref","unstructured":"Gualano G, Musso M, Mencarini P, Mosti S, Cerva C, Vittozzi P, et al. Safety and effectiveness of BPaL-based regimens to treat multidrug-resistant TB: first experience of an Italian tuberculosis referral hospital. Antibiotics (Basel). 2024;14(1).","DOI":"10.3390\/antibiotics14010007"},{"key":"13135_CR35","doi-asserted-by":"publisher","first-page":"100408","DOI":"10.1016\/j.jctube.2023.100408","volume":"34","author":"P Sangsayunh","year":"2024","unstructured":"Sangsayunh P, Sanchat T, Chuchottaworn C, Cheewakul K, Rattanawai S. The use of BPaL containing regimen in the MDR\/PreXDR TB treatments in Thailand. J Clin Tuberc Other Mycobact Dis. 2024;34:100408.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"13135_CR36","unstructured":"Effectiveness of BPaL regimens. analysis of the first country cohort of operational research."},{"issue":"1","key":"13135_CR37","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1186\/s12879-024-09960-3","volume":"24","author":"Y Abraham","year":"2024","unstructured":"Abraham Y, Assefa DG, Hailemariam T, Gebrie D, Debela DT, Geleta ST, et al. Efficacy and safety of shorter multidrug-resistant or rifampicin-resistant tuberculosis regimens: a network meta-analysis. BMC Infect Dis. 2024;24(1):1087.","journal-title":"BMC Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13135-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13135-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13135-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:15:36Z","timestamp":1777853736000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13135-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13135"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13135-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"7 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anonymity was preserved. Patient names were not used. Each patient had a unique identifier, and confidentiality was maintained. The investigator obtained ethical approval from St. Peter specialized Hospital institutional research ethics committee, ALERT Hospital academic and research department, and Dilla university college of medical, health sciences institutional review board. In addition, written permission to carry out the research was obtained from all selected public hospitals. Due to the retrospective nature of the study, informed consent was waived by the St. Peter specialized Hospital institutional research ethics committee, ALERT Hospital academic and research department, and Dilla university college of medical, health sciences institutional review board. The principal investigator and the research team had access to the collected data. The study was done in compliance with the declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"879"}}